Portfolio company Day One Biopharmaceuticals was acquired by Servier in March 2026.
Day One Biopharmaceuticals is dedicated to developing targeted cancer therapies for children and adults, focusing on innovative drug development to provide new treatment options for patients in need
Day One Biopharmaceuticals is dedicated to developing targeted cancer therapies for children and adults, focusing on innovative drug development to provide new treatment options for patients in need.